PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery

Cell Reports

Volumn 15, Issue 5, 2016, Pages 944-950

  Ramracheya, Reshma D ^a   McCulloch, Laura J ^a   Clark, Anne ^a   Wiggins, David ^a   Johannessen, Helene ^b   Olsen, Magnus Kringstad ^b   Cai, Xing ^b   Zhao, Chun Mei ^b   Chen, Duan ^b   Rorsman, Patrik ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; PEPTIDE YY; TRANSCRIPTION FACTOR PDX 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; GLUCAGON RELEASE; GOTO KAKIZAKI RAT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INSULIN RELEASE; LONG TERM EXPOSURE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; RAT; REMISSION; ROUX EN Y GASTRIC BYPASS; STOMACH BYPASS; ANIMAL; GASTRIC BYPASS SURGERY; METABOLISM; PATHOLOGY; SECRETION (PROCESS); WISTAR RAT;

ADULT; ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC BYPASS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; PEPTIDE YY; RATS, WISTAR; TRANSCRIPTION, GENETIC;

EID: 84963967658     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.03.091     Document Type: Article

References (28)

1. Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89:1070-1077.
2. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., Ghatei M.A., Bloom S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 2003, 349:941-948.
3. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
4. Cerf M.E. Transcription factors regulating beta-cell function. Eur. J. Endocrinol. 2006, 155:671-679.
5. Chan J.L., Mun E.C., Stoyneva V., Mantzoros C.S., Goldfine A.B. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 2006, 14:194-198.
6. Chandarana K., Gelegen C., Irvine E.E., Choudhury A.I., Amouyal C., Andreelli F., Withers D.J., Batterham R.L. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol. Metab. 2013, 2:142-152.
7. Chimerel C., Emery E., Summers D.K., Keyser U., Gribble F.M., Reimann F. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 2014, 9:1202-1208.
8. Clements R.H., Gonzalez Q.H., Long C.I., Wittert G., Laws H.L. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am. Surg. 2004, 70:1-4. discussion 4-5.
9. Höög A., Hu W., Abdel-Halim S.M., Falkmer S., Qing L., Grimelius L. Ultrastructural localization of insulin-like growth factor-2 (IGF-2) to the secretory granules of insulin cells: a study in normal and diabetic (GK) rats. Ultrastruct. Pathol. 1997, 21:457-466.
10. Jørgensen N.B., Dirksen C., Bojsen-Møller K.N., Jacobsen S.H., Worm D., Hansen D.L., Kristiansen V.B., Naver L., Madsbad S., Holst J.J. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013, 62:3044-3052.
11. Kodama Y., Johannessen H., Furnes M.W., Zhao C.M., Johnsen G., Mårvik R., Kulseng B., Chen D. Mechanistic comparison between gastric bypass vs. duodenal switch with sleeve gastrectomy in rat models. PLoS ONE 2013, 8:e72896.
12. Lake S.P., Bassett P.D., Larkins A., Revell J., Walczak K., Chamberlain J., Rumford G.M., London N.J., Veitch P.S., Bell P.R., et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes 1989, 38(Suppl 1):143-145.
13. Lee Y., Berglund E.D., Wang M.Y., Fu X., Yu X., Charron M.J., Burgess S.C., Unger R.H. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc. Natl. Acad. Sci. USA 2012, 109:14972-14976.
14. Lindqvist A., Spégel P., Ekelund M., Mulder H., Groop L., Hedenbro J., Wierup N. Effects of ingestion routes on hormonal and metabolic profiles in gastric-bypassed humans. J. Clin. Endocrinol. Metab. 2013, 98:E856-E861.
15. Marchetti P., Lupi R., Bugliani M., Kirkpatrick C.L., Sebastiani G., Grieco F.A., Del Guerra S., D'Aleo V., Piro S., Marselli L., et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 2012, 55:3262-3272.
16. Mokadem M., Zechner J.F., Margolskee R.F., Drucker D.J., Aguirre V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol. Metab. 2014, 3:191-201.
17. Persaud S.J., Bewick G.A. Peptide YY: more than just an appetite regulator. Diabetologia 2014, 57:1762-1769.
18. Pittner R.A., Moore C.X., Bhavsar S.P., Gedulin B.R., Smith P.A., Jodka C.M., Parkes D.G., Paterniti J.R., Srivastava V.P., Young A.A. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 2004, 28:963-971.
19. Pournaras D.J., Osborne A., Hawkins S.C., Vincent R.P., Mahon D., Ewings P., Ghatei M.A., Bloom S.R., Welbourn R., le Roux C.W. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann. Surg. 2010, 252:966-971.
20. Ramracheya R., Ward C., Shigeto M., Walker J.N., Amisten S., Zhang Q., Johnson P.R., Rorsman P., Braun M. Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. Diabetes 2010, 59:2198-2208.
21. Salehi M., Prigeon R.L., D'Alessio D.A. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011, 60:2308-2314.
22. Sam A.H., Gunner D.J., King A., Persaud S.J., Brooks L., Hostomska K., Ford H.E., Liu B., Ghatei M.A., Bloom S.R., Bewick G.A. Selective ablation of peptide YY cells in adult mice reveals their role in beta cell survival. Gastroenterology 2012, 143:459-468.
23. Shin A.C., Zheng H., Townsend R.L., Sigalet D.L., Berthoud H.R. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 2010, 151:1588-1597.
24. Tan T.M., Salem V., Troke R.C., Alsafi A., Field B.C., De Silva A., Misra S., Baynes K.C., Donaldson M., Minnion J., et al. Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose. J. Clin. Endocrinol. Metab. 2014, 99:E2317-E2324.
25. Tremaroli V., Karlsson F., Werling M., Ståhlman M., Kovatcheva-Datchary P., Olbers T., Fändriks L., le Roux C.W., Nielsen J., Bäckhed F. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 2015, 22:228-238.
26. Unger R.H., Cherrington A.D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 2012, 122:4-12.
27. Ye J., Hao Z., Mumphrey M.B., Townsend R.L., Patterson L.M., Stylopoulos N., Münzberg H., Morrison C.D., Drucker D.J., Berthoud H.R. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014, 306:R352-R362.
28. Zhang Q., Ramracheya R., Lahmann C., Tarasov A., Bengtsson M., Braha O., Braun M., Brereton M., Collins S., Galvanovskis J., et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013, 18:871-882.